DexCom develops continuous glucose monitoring systems for people with diabetes. Its wearable sensors track glucose levels and transmit readings to mobile devices and compatible insulin delivery systems, helping users manage treatment decisions. Revenue is driven largely by recurring sensor demand, growing adoption among eligible patients, and integration with digital diabetes-care tools.
DexCom Inc. (DXCM) has a MarketKingdoms composite score of 70.2 (B+), an B-range rating. It ranks 307th of 1,866 covered companies, 11th of 78 in Healthcare (sector average 64.5) and 1st of 10 in Medical Devices. Scores as of 2026-10-25.
Its strongest lenses are KPI momentum at 87 (Healthcare average 78) and Stock selection at 85 (Healthcare average 79). Its weakest lenses are Price (valuation) at 44 (sector average 50) and Trend (momentum) at 51 (sector average 50).
| Lens | Type | DXCM | Healthcare average | Medical Devices average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 85 | 79 | 78 | 83rd |
| KPI momentum | Research signal | 87 | 78 | 75 | 78th |
| Catalyst watch | Research signal | 73 | 74 | 75 | 41st |
| Price (valuation) | Fundamental lens | 44 | 50 | 54 | 38th |
| Expansion (growth) | Fundamental lens | 81 | 50 | 57 | 91st |
| Quality (profitability) | Fundamental lens | 74 | 50 | 53 | 85th |
| Trend (momentum) | Fundamental lens | 51 | 50 | 27 | 49th |
The most recent call analysed was held on 2026-07-30 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -25.0%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 1.28, sector beta -0.58, industry beta 1.01; the factor model explains 21% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Edwards Lifesciences Corp. (EW) | 63.9 | B- | +1.7% |
| STERIS plc (STE) | 63.9 | B- | -7.7% |
| Zimmer Biomet Holdings Inc. (ZBH) | 62.7 | B- | -12.1% |
| Medtronic Plc (MDT) | 62.5 | B- | -5.9% |
| Abbott Laboratories (ABT) | 60.9 | B- | -6.4% |
| GE HealthCare Technologies Inc. (GEHC) | 60.4 | B- | -5.8% |
| Insulet Corp. (PODD) | 59.2 | B- | -18.8% |
| Stryker Corp. (SYK) | 59.2 | B- | -3.3% |
DexCom Inc. financial statements · Healthcare sector ranking · Medical Devices industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.